Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC-HIPC: Neonatal Vaccine Immunogenicity
NCT03246230Completed
- Sponsor
- Boston Children's Hospital
- Start
- Sep 2017
- Primary completion
- Aug 2022
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 2
01
Overview
Randomised, open-label trial of Hepatitis B vaccine in hepatitis B (HBV) (4 arms), sponsored by Boston Children's Hospital. Primary endpoint: Molecular signature correlating with anti-hepatitis B vaccine antibody response at 1 month. Started Sep 2017; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03246230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246230.